Sargent Investment Group LLC Boosts Stock Position in MediWound Ltd. (NASDAQ:MDWD)

Sargent Investment Group LLC grew its holdings in MediWound Ltd. (NASDAQ:MDWD) by 7.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 109,194 shares of the biopharmaceutical company’s stock after purchasing an additional 7,125 shares during the period. Sargent Investment Group LLC owned about 1.19% of MediWound worth $1,111,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Silverberg Bernstein Capital Management LLC bought a new stake in shares of MediWound during the fourth quarter valued at approximately $803,000. Hedge funds and other institutional investors own 46.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MDWD. StockNews.com cut MediWound from a “hold” rating to a “sell” rating in a research note on Saturday, March 30th. HC Wainwright reissued a “buy” rating and set a $28.00 price target on shares of MediWound in a research report on Friday, March 22nd.

MediWound Price Performance

Shares of NASDAQ:MDWD traded up $0.58 during trading hours on Friday, hitting $18.24. The company’s stock had a trading volume of 73,119 shares, compared to its average volume of 79,759. The firm’s fifty day moving average price is $15.45 and its 200 day moving average price is $12.05. MediWound Ltd. has a 52 week low of $7.10 and a 52 week high of $18.75. The company has a market capitalization of $173.13 million, a price-to-earnings ratio of -23.69 and a beta of 0.93.

MediWound (NASDAQ:MDWD) last posted its earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. MediWound had a negative return on equity of 20.22% and a negative net margin of 35.94%. The company had revenue of $5.34 million during the quarter, compared to analyst estimates of $5.33 million. On average, equities research analysts predict that MediWound Ltd. will post -1.93 earnings per share for the current fiscal year.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.